Idiopathic interstitial pneumonias
Conditions
Interventions
Administration of omega-3 fatty acids
Sponsors
Graduate School of Medicine, Nippon Medical School
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1)Patients with written informed consent. (2)Patients diagnosed as IIPs (Idiopathic Pulmonary Fibrosis or fibrotic Nonspecific Interstitial Pneumonia) (3)Patients with hypertriglyceridemia defined as a triglyceride level exceeded 150 mg/dL. (4)Patients whose serum KL-6 levels exceeded 500 U/mL or serum SP-D levels exceeded 110 ng/mL
Exclusion criteria
Exclusion criteria: (1)A pregnant woman or the woman who may be pregnant. (2)Patients who have received immunosuppressants (e.g. Ciclosporin or Cyclophosphamide), pirfenidone, or N-acetylcysteine within 6 months prior to participation. (3)Patients who began oral corticosteroids therapy within 6 months prior to participation. Patients who have received high-dose corticosteroids (>10 mg prednisolone daily) (4)Patients taking DHA or EPA within 3 months prior to participation (5)Patients with unstable IIPs. (6)Patients with severe anemia, liver disease, renal disease, heart disease or bleeding. (7)In addition, the patients who are not eligible for participation judged by a doctor
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes of the biomarkers of IIPs | — |
Countries
Japan
Contacts
Public ContactKenichiro Atsumi
Graduate School of Medicine, Nippon Medical School Department of Pulmonary Medicine and Oncology
Outcome results
None listed